Spots Global Cancer Trial Database for platinum sensitive
Every month we try and update this database with for platinum sensitive cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Olaparib in Patients With Recurrent Ovarian Cancer Wild Type for Germline and Somatic BRCA 1 and 2 Genes: The MITO 31 Translational Study | NCT04091204 | BRCA Wild Type ... | Olaparib tablet... | 18 Years - | National Cancer Institute, Naples | |
| Carboplatin/Pralatrexate in Recurrent Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer | NCT01188876 | Ovarian Cancer Fallopian Tube ... Peritoneal Canc... | carboplatin pralatrexate Folic Acid Vitamin B12 Inj... | 18 Years - | Massachusetts General Hospital | |
| A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | NCT01846611 | Ovarian Neoplas... Peritoneal Neop... Fallopian Tube ... | Trabectedin DOXIL Dexamethasone DOXIL | 18 Years - | Janssen Research & Development, LLC | |
| OSCA - Olaparib Standard of CAre Study | NCT02262273 | Platinum-sensit... | Data Collection | 18 Years - | AstraZeneca | |
| Veliparib and Topotecan for Relapsed Ovarian Cancer With Negative or Unknown BRCA Status | NCT01690598 | Ovarian Cancer | Veliparib Topotecan | 18 Years - | Vejle Hospital | |
| Phase II Multicenter Study of Durvalumab and Olaparib in Platinum tReated Advanced Triple Negative Breast Cancer (DORA) | NCT03167619 | Triple Negative... | Olaparib Oral P... Olaparib Oral P... | 21 Years - | Duke University | |
| Bevacizumab Beyond Progression in Platinum Sensitive Ovarian Cancer | NCT01802749 | Recurrent Ovari... | Bevacizumab Paclitaxel Carboplatin pegylated lipos... Gemcitabine | 18 Years - | National Cancer Institute, Naples | |
| Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3) | NCT01968213 | Ovarian Cancer Fallopian Tube ... Peritoneal Canc... | Rucaparib Placebo | 18 Years - | pharmaand GmbH | |
| CPI-0209 Plus Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer | NCT05942300 | Recurrent Ovari... | CPI-0209 carboplatin | 18 Years - | University of Pittsburgh | |
| Lurbinectedin Combined With Durvalumab in Pre-treated Patients With Extensive Stage Small-cell Lung Cancer | NCT05572476 | Small Cell Lung... Platinum-Sensit... Extensive-stage... | Association of ... Association of ... | 18 Years - | Institut Bergonié | |
| A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2) | NCT01891344 | Ovarian Cancer Epithelial Ovar... Fallopian Tube ... Peritoneal Canc... | Oral rucaparib | 18 Years - | pharmaand GmbH | |
| Olaparib in Patients With Recurrent Ovarian Cancer Wild Type for Germline and Somatic BRCA 1 and 2 Genes: The MITO 31 Translational Study | NCT04091204 | BRCA Wild Type ... | Olaparib tablet... | 18 Years - | National Cancer Institute, Naples | |
| Bevacizumab Beyond Progression in Platinum Sensitive Ovarian Cancer | NCT01802749 | Recurrent Ovari... | Bevacizumab Paclitaxel Carboplatin pegylated lipos... Gemcitabine | 18 Years - | National Cancer Institute, Naples | |
| Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy | NCT01874353 | Platinum Sensit... BRCA Mutated Relapsed Ovaria... Following Compl... | Olaparib 300mg ... Placebo to matc... | 18 Years - 130 Years | AstraZeneca | |
| Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer | NCT04519151 | Ovarian Neoplas... Carcinoma, Ovar... Neoplasm of Sto... Ovarian Disease... Genital Neoplas... Ovarian Epithel... Urogenital Neop... Neoplasms, Glan... | Pembrolizumab Lenvatinib | 18 Years - | Sheba Medical Center | |
| Docetaxel/Carboplatin Versus Docetaxel/Caelyx in Pretreated Patients With Ovarian Carcinoma | NCT00758732 | Ovarian Cancer | Docetaxel Carboplatin Docetaxel Liposomal doxor... | 18 Years - | Hellenic Oncology Research Group | |
| A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes | NCT04171700 | Solid Tumor | Rucaparib | 18 Years - | pharmaand GmbH | |
| Comparison of QoL Between Trabectedin/PLD and Standard Platinum-based Therapy in Patients With Platinum Sensitive Recurrent Ovarian Cancer | NCT03164980 | Quality of Life Ovarian Cancer Recurrent Ovari... | Trabectidin (Yo... | 18 Years - | North Eastern German Society of Gynaecological Oncology | |
| A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II) | NCT01482715 | Ovarian Cancer Fallopian Tube ... Peritoneal Canc... Advanced Solid ... | Rucaparib | 18 Years - | pharmaand GmbH | |
| A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2) | NCT01891344 | Ovarian Cancer Epithelial Ovar... Fallopian Tube ... Peritoneal Canc... | Oral rucaparib | 18 Years - | pharmaand GmbH | |
| Veliparib and Topotecan for Relapsed Ovarian Cancer With Negative or Unknown BRCA Status | NCT01690598 | Ovarian Cancer | Veliparib Topotecan | 18 Years - | Vejle Hospital | |
| ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients | NCT02855944 | Ovarian Cancer Epithelial Ovar... Fallopian Tube ... Peritoneal Canc... | Chemotherapy Rucaparib | 18 Years - | pharmaand GmbH | |
| Olaparib in Patients With Recurrent Ovarian Cancer Wild Type for Germline and Somatic BRCA 1 and 2 Genes: The MITO 31 Translational Study | NCT04091204 | BRCA Wild Type ... | Olaparib tablet... | 18 Years - | National Cancer Institute, Naples | |
| ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients | NCT02855944 | Ovarian Cancer Epithelial Ovar... Fallopian Tube ... Peritoneal Canc... | Chemotherapy Rucaparib | 18 Years - | pharmaand GmbH | |
| A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer | NCT01847274 | Ovarian Neoplas... Platinum Sensit... | Active comparat... placebo | 18 Years - | Tesaro, Inc. | |
| Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer | NCT01081951 | Ovarian Cancer | olaparib paclitaxel carboplatin paclitaxel Drug: carboplat... | 18 Years - 125 Years | AstraZeneca | |
| Olaparib Tablets Maintenance Monotherapy Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy | NCT03534453 | Relapsed Ovaria... Following Compl... Platinum Sensit... | Olaparib 300mg ... | 18 Years - 130 Years | AstraZeneca | |
| Comparison of QoL Between Trabectedin/PLD and Standard Platinum-based Therapy in Patients With Platinum Sensitive Recurrent Ovarian Cancer | NCT03164980 | Quality of Life Ovarian Cancer Recurrent Ovari... | Trabectidin (Yo... | 18 Years - | North Eastern German Society of Gynaecological Oncology | |
| A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | NCT01846611 | Ovarian Neoplas... Peritoneal Neop... Fallopian Tube ... | Trabectedin DOXIL Dexamethasone DOXIL | 18 Years - | Janssen Research & Development, LLC |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
